All In Biotech

Drug Trial Radar · NCT07227636

A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy

Phase II Study of Adjuvant Botensilimab in Combination With Balstilimab in Patients With Colorectal Cancer and Persistent Circulating Tumor DNA Following Surgery and Chemotherapy

Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 284 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

284

Planned (sponsor's estimate)

Start

Nov 7, 2025

Primary completion

Nov 2030

Study completion Nov 2030

Sponsor

Lead sponsor
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Agenus Inc.
First posted
Nov 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The researchers are doing this study to find out whether the combination of botensilimab and balstilimab (BOT/BAL), followed by balstilimab alone, is an effective treatment for people with microsatellite stable (MSS) colorectal cancer or colorectal liver metastases (CRLM) who have measurable residual disease (MRD) after standard treatment with surgery and chemotherapy or total neoadjuvant therapy (TNT).

Conditions

  • Colorectal Cancer
  • Rectal Cancer

Interventions

  • BotensilimabDrug

    All patients will receive botensilimab IV on day 1 of the 42 day cycle for 4 doses

  • BalstilimabDrug

    All patients will receive balstilimab IV on days 1, 15, and 29 of the 42 day cyclePatient then continues balstilimab alone for an additional two cycles IV on days 1, 15, and 29 of the 42 day cycle.

  • PlaceboOther

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of ctDNA clearance (Cohort 1a)Time frame: 6 months
  2. Rate of ctDNA clearance (Cohort 1b)Time frame: 6 months
  3. Recurrence-free survival (RFS) (Cohort 2a)Time frame: 1 year
  4. Recurrence-free survival (RFS) (Cohort 2b)Time frame: 1 year

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

    Basking Ridge, New Jersey · Recruiting

  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities)

    Middletown, New Jersey · Recruiting

  • Memorial Sloan Kettering Bergen (Limited Protocol Activities)

    Montvale, New Jersey · Recruiting

  • Memorial Sloan Kettering Commack (Limited Protocol Activities)

    Commack, New York · Recruiting

  • Memorial Sloan Kettering Westchester (All Protocol Activities)

    Harrison, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)

    New York, New York · Recruiting

  • Memorial Sloan Kettering Nassau (Limited Protocol Activities)

    Rockville Centre, New York · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.